| Symbol | TECX |
|---|---|
| Name | TECTONIC THERAPEUTIC, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE KENDALL SQUARE,BUILDING 300, SUITE 201, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 914-8420 |
| Fax | — |
| — | |
| Website | https://www.tectonictx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001681087 |
| Description | Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Companys lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT). Additional info from NASDAQ: |
REICIN ALISE 🔴 sold 924 shares of Tectonic Therapeutic, Inc. (TECX) at $30.34 Transaction Date: Jun 20, 2026 | Filing ID: 000012
Read moreLochner Daniel 🟢 acquired 7.5K shares (1 derivative) of Tectonic Therapeutic, Inc. (TECX) at $16.80 Transaction Date: Jun 11, 2026 | Filing ID: 000006
Read more(85% Positive) TECTONIC THERAPEUTIC, INC. (TECX) Announces Enrollment Update for enrollment Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreSPRINGER TIMOTHY A 🟢 acquired 10.2K shares (1 derivative) of Tectonic Therapeutic, Inc. (TECX) at $28.56 Transaction Date: Jun 09, 2026 | Filing ID: 000003
Read moreTipirneni Praveen P. 🟢 acquired 10.2K shares (1 derivative) of Tectonic Therapeutic, Inc. (TECX) at $28.56 Transaction Date: Jun 09, 2026 | Filing ID: 000003
Read moreDonenberg Phillip B. 🟢 acquired 10.2K shares (1 derivative) of Tectonic Therapeutic, Inc. (TECX) at $28.56 Transaction Date: Jun 09, 2026 | Filing ID: 000010
Read moreChutter Jessica Caroline 🟢 acquired 20.4K shares (1 derivative) of Tectonic Therapeutic, Inc. (TECX) at $29.10 Transaction Date: Jun 08, 2026 | Filing ID: 000007
Read moreTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Read moreNew Form 3 - Tectonic Therapeutic, Inc. <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0002123815-26-000006 <b>Size:</b> 8 KB
Read more(30% Negative) TECTONIC THERAPEUTIC, INC. (TECX) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06616974 | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart … | Phase2 | Pulmonary Hypertension | Active_Not_Recruiting | 2024-09-04 | 2027-01-05 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT06616974 |
| TX000045- Dose B | Other | Phase PHASE2 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT06616974 |
| TX000045- Dose A | Other | Phase PHASE2 | Pulmonary Hypertension | ACTIVE_NOT_RECRUITING | NCT06616974 |
| Placebo | Other | Phase PHASE2 | Pulmonary Hypertension | RECRUITING | NCT06616974 |
| TX000045- Dose B | Other | Phase PHASE2 | Pulmonary Hypertension | RECRUITING | NCT06616974 |
| TX000045- Dose A | Other | Phase PHASE2 | Pulmonary Hypertension | RECRUITING | NCT06616974 |